<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37718187</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>43</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection.</ArticleTitle><Pagination><StartPage>6470</StartPage><EndPage>6482</EndPage><MedlinePgn>6470-6482</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2023.08.083</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(23)01049-6</ELocationID><Abstract><AbstractText>Coxsackievirus A2 (CVA2) is one of the causative agents of hand-foot-and-mouth disease (HFMD), which poses a great challenge for global public health. However, presently, there are no available commercial vaccines or antivirals to prevent CVA2 infection. Here, we present an inactivated Vero cell-based whole CVA2 vaccine candidate and evaluate its safety and efficacy in this study. Neonatal BALB/c mice were vaccinated at 5 and 7 days old, respectively, and then challenged with either homologous or heterologous strain of CVA2 at a lethal dose at 10 days old. The inactivated whole CVA2 vaccine candidate showed a high protective efficacy. Additionally, our inactivated vaccine stimulated the production of CVA2-specific IgG1 and IgG2a antibodies in vivo and high titers of neutralization antibodies (NtAbs) in the serum of immunized mice. Maternal immunization with the inactivated CVA2 vaccine provided full protection to pups against lethal infection. Compared with mice inoculated with only alum, the viral loads were decreased, and pathological changes were relieved in tissue samples of immunized mice. Moreover, the transcription levels of some genes related to cytokines (IFN-γ and TNF-α, MCP-1, IL-6, CXCL-10 etc.) were significantly reduced. The number of immune cells and levels of cytokines in peripheral blood of mice inoculated with only alum were higher than that of immunized mice. It is noteworthy that this vaccine showed a good cross-immunity efficacy against Enterovirus A71 (EVA71) challenge. In conclusion, our findings suggest that this experimental inactivated CVA2 vaccine is a promising component of polyvalent vaccines related to HFMD in the near future.</AbstractText><CopyrightInformation>Copyright © 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuexia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China; Department of Infectious Disease Control and Prevention, Jiangshan Center for Disease Control and Prevention, Jiangshan 324100, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Wangquan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Tiantian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Peiyu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Junwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Department of Infectious Disease Control and Prevention, Jiangshan Center for Disease Control and Prevention, Jiangshan 324100, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuaiyin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yuefei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China. Electronic address: jyf201907@zzu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Guangcai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, China; Academy of Medical Science, Zhengzhou University, Zhengzhou 450001, Henan, China. Electronic address: gcduan@zzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A2</Keyword><Keyword MajorTopicYN="N">Cross immunity</Keyword><Keyword MajorTopicYN="N">Hand-foot-and-mouth disease</Keyword><Keyword MajorTopicYN="N">Mouse model</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>18</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>17</Day><Hour>21</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37718187</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.08.083</ArticleId><ArticleId IdType="pii">S0264-410X(23)01049-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle>